Response to: Letter to the editor regarding: Real‑world rebound pattern of serum collagen type I C‑telopeptide after denosumab discontinuation and zoledronate rescue in postmenopausal osteoporosis and cancer treatment‑induced bone loss
- 2 June 2026
- journal article
- Published by Springer Nature in Osteoporosis International
- Vol. 37 (5) , 1407-1408
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Real-world rebound pattern of serum collagen type I C-telopeptide after denosumab discontinuation and zoledronate rescue in postmenopausal osteoporosis and cancer treatment-induced bone lossOsteoporosis International, 2026
- Non-metastatic breast cancer patients discontinuing aromatase inhibitor on denosumab: what next?Osteoporosis International, 2026
- Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than Single Infusion?The Journal of Clinical Endocrinology & Metabolism, 2024
- Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTSThe Journal of Clinical Endocrinology & Metabolism, 2020